Financial Performance - The company's revenue for Q1 2024 was ¥256,905,255.97, a decrease of 22.75% compared to ¥332,570,440.03 in the same period last year[5] - Net profit attributable to shareholders was ¥1,739,546.28, down 98.66% from ¥130,078,277.07 year-on-year[5] - Basic and diluted earnings per share were both ¥0.02, a decline of 98.20% from ¥1.11 in the same period last year[5] - Total operating revenue for Q1 2024 was CNY 256.91 million, a decrease of 22.7% compared to CNY 332.57 million in the same period last year[17] - Net profit for Q1 2024 was CNY 2.43 million, a significant decline from CNY 130.56 million in Q1 2023[19] - Earnings per share (EPS) for Q1 2024 was CNY 0.02, down from CNY 1.11 in the previous year[20] Cash Flow and Assets - The net cash flow from operating activities decreased by 74.90%, amounting to ¥35,613,948.24 compared to ¥141,897,609.33 in the previous year[5] - The company's cash and cash equivalents decreased to RMB 336,898,188.19 from RMB 409,952,778.49, a decline of about 17.8%[14] - The net cash flow from investment activities was -50,383,705.09 CNY, compared to a positive cash flow of 14,444,132.76 CNY in the previous year[22] - The total cash inflow from financing activities was 13,585,000.00 CNY, down from 43,500,000.00 CNY year-over-year[22] - The net cash flow from financing activities was -58,284,833.45 CNY, compared to a positive cash flow of 37,689,155.15 CNY in the previous year[22] - The net increase in cash and cash equivalents was -73,054,590.30 CNY, contrasting with an increase of 194,030,897.24 CNY in the same period last year[22] - The ending balance of cash and cash equivalents was 336,898,188.19 CNY, down from 625,681,712.53 CNY at the end of the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,050,673,686.95, down 4.15% from ¥2,139,389,690.42 at the end of the previous year[5] - The company reported a total asset of RMB 2,050,673,686.95 as of March 31, 2024, down from RMB 2,118,970,407.99 at the beginning of the period, reflecting a decrease of approximately 3.2%[14] - The total liabilities decreased to RMB 502,069,257.46 from RMB 551,030,749.96, representing a reduction of approximately 8.9%[15] - The company's inventory decreased to RMB 178,406,941.41 from RMB 188,202,443.04, a decline of about 5.5%[14] - The company's accounts receivable increased to RMB 19,968,064.10 from RMB 18,685,725.04, an increase of approximately 6.9%[14] - The company reported a decrease in current liabilities to RMB 192,838,263.91 from RMB 233,773,144.62, a reduction of approximately 17.5%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,786[9] - The largest shareholder, Yu Yangchao, holds 30.63% of the shares, totaling 36,107,628 shares[9] - The total equity attributable to shareholders of the parent company was CNY 1.53 billion, down from CNY 1.55 billion in the previous year[19] - The company repurchased 2,346,000 shares, accounting for 1.99% of the total share capital, with a total transaction amount of RMB 30,004,529.29[12] - The company plans to use between RMB 30 million and RMB 60 million for share repurchase to implement equity incentive plans[12] Operational Insights - The company's main business income decreased by 22.75%, primarily due to a decline in product sales prices[7] - The cost of main business increased by 25.33%, attributed to the production capacity increase from new factories coming online[7] - Research and development expenses decreased by 41.98%, mainly due to the completion of certain R&D projects[7] - Research and development expenses for Q1 2024 were CNY 1.86 million, down 42% from CNY 3.20 million in the same period last year[17] - The company reported a decrease in sales expenses to CNY 2.98 million from CNY 1.94 million year-over-year[17] - The company established two new subsidiaries focused on bio-organic fertilizers, expected to enhance the value of by-products and positively impact performance in the second half of 2024[11] - The company plans to focus on market expansion and new product development in the upcoming quarters[19] Audit Information - The company did not undergo an audit for the first quarter report[23]
华绿生物(300970) - 2024 Q1 - 季度财报